Name
Kazuyuki Inoue

Current Status
Associate Professor
Department of Clinical Pharmacology & Genetics,
School of Pharmaceutical Science, University of Shizuoka.

Date of Birth
November 1972

Education
2004

Ph.D. in Medicine, Akita University

1997

M.S. in Pharmaceutical Science, Tohoku University

1995

B.S. in Pharmaceutical Science, Tohoku University

Experience2016.10-present

Associate Professor
Department of Clinical Pharmacology & Genetics,
School of Pharmaceutical Science, University of Shizuoka.

2008.4-2016.9

Assistant Professor
Department of Clinical Pharmacology & Genetics,
School of Pharmaceutical Science, University of Shizuoka.

2002.4-2008.3

Chief Pharmacist

Department of Pharmaceutical Science, Akita University
Hospital
2000.4-2002.3

Pharmacist
Department of Pharmaceutical Science, Tohoku University
Hospital

1997.4-2000.3

Pharmacist
Department of Pharmaceutical Science, Akita University
HospitalAward2003

The Pharmaceutical Society of Japan Tohoku BranchAward for Young Scientists

Recent Publications (From 2008)
1. Yokoi M, Tsuji D, Suzuki K, Kawasaki Y, Nakao M, Ayuhara H, Kogure Y, Shibata
K, Hayashi T, Hirai K, Inoue K, Hama T, Takeda K, Nishio M, Itoh K. Genetic risk
factors for chemotherapy-induced nausea and vomiting in patients with cancer
receiving cisplatin-based chemotherapy. Support Care Cancer. 26(5), 1505-1513(2018)
2. Hirai K, Shirai T, Suzuki M, Akamatsu T, Suzuki T, Hayashi I, Yamamoto A, Akita
T, Morita S, Asada K, Tsuji D, Inoue K, Itoh K.

A clustering approach to identify

and characterize the asthma and chronic obstructive pulmonary disease overlap
phenotype. Clin Exp Allergy. 47(11), 1374-1382 (2017)
3. Otake A, Tsuji D, Taku K, Kawasaki Y, Yokoi M, Nakamori H, Osada M, Matsumoto

M, Inoue K, Hirai K, Itoh K. Chemotherapy-induced neutropenia as a prognostic
factor in patients with metastatic pancreatic cancer treated with gemcitabine. EurJ Clin Pharmacol. 73(8), 1033-1039 (2017).
4. Tsuji D, Yokoi M, Suzuki K, Daimon T, Nakao M, Ayuhara H, Kogure Y, Shibata K,Hayashi T, Hirai K, Inoue K, Hama T, Takeda K, Nishio M, Itoh K. Influence of
ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients withcancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics
study. Pharmacogenomics J. 17(5), 435-440 (2017)
5. Tsuji D, Ikeda M, Yamamoto K, Nakamori H, Kim Y, Kawasaki Y, Otaki A, Yokoi
M, Inoue K, Hirai K, Nakamichi H, Tokou U, Shiokawa M, Itoh K. Drug-related
genetic polymorphisms affecting severe chemotherapy-induced neutropenia inbreast cancer patients: A hospital-based observational study. Medicine. 95(44),e5151 (2016)
6. Hirai K, Ishii H, Shimoshikiryo T, Shimomura T, Tsuji D, Inoue K, Kadoiri T, ItohK. Augmented renal clearance in patients with febrile neutropenia is associatedwith increased risk for subtherapeutic concentrations of vancomycin. Ther DrugMonit. 38(6), 706-710 (2016)
7. Hirai K, Shimomura T, Moriwaki H, Ishii H, Shimoshikiryo T, Tsuji D, Inoue K,Kadoiri T, Itoh K. Risk factors for hypernatremia in patients with short- and longterm tolvaptan treatment. Eur J Clin Pharmacol. 72(10), 1177-1183 (2016)
8. Inoue K, Murofushi T, Nagaoka K, Ando N, Hakamata Y, Suzuki A, Umemura A,Yoshida Y, Hirai K, Tsuji D, Itoh K. Influence of genetic polymorphisms andconcomitant anxiolytic doses on antidepressant maintenance doses in Japanesepatients with depression. Biol Pharm Bull. 39(9), 1508-13 (2016)

9. Inoue K, Yamamoto Y, Suzuki E, Takahashi T, Umemura A, Takahashi Y, Imai K,Inoue Y, Hirai K, Tsuji D, Itoh K. Factors that influence the pharmacokinetics oflamotrigine in Japanese patients with epilepsy. Eur J Clin Pharmacol. 72(5), 555562 (2016)
10. Inoue K, Takahashi T, Yamamoto Y, Suzuki E, Takahashi Y, Imai K, Inoue Y, Hirai
K, Tsuji D, Itoh K. Influence of glutamine synthetase gene polymorphisms on thedevelopment of hyperammonemia during valproic acid-based therapy. Seizure.
33, 76-80 (2015)
11. Tazoe Y, Hayashi H, Tsuboi S, Shioura T, Matsuyama T, Yamada H, Hirai K, Tsuji
D, Inoue K, Sugiyama T, Itoh K. Reduced folate carrier 1 gene expression levels
are correlated with methotrexate efficacy in Japanese patients with rheumatoid
arthritis. Drug Metab Pharmacokinet. 30(3), 227-30 (2015)12. Hirai K, Yamada Y, Hayashi H, Tanaka M, Izumiya K, Suzuki M, Yoshizawa M,
Moriwaki H, Akimoto T, Tsuji D, Inoue K, Itoh K. Plasma vitamin K concentrations
depend on CYP4F2 polymorphism and influence on anticoagulation in Japanesepatients with warfarin therapy. Thromb Res. 135(5), 861-6 (2015)
13. Ikeda M, Tsuji D, Yamamoto K, Kim YI, Daimon T, Iwabe Y, Hatori M, Makuta R,Hayashi H, Inoue K, Nakamichi H, Shiokawa M, Itoh K. Relationship between
ABCB1 gene polymorphisms and severe neutropenia in patients with breast
cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug Metab
Pharmacokinet. 30(2), 149-53 (2015)
14. Inoue K, Suzuki E, Takahashi T, Yamamoto Y, Yazawa R, Takahashi Y, Imai K,Miyakawa K, Inoue Y, Tsuji D, Hayashi H, Itoh K. 4217C>A polymorphism incarbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia

development during valproic acid-based therapy. Epilepsy Res. 108(6), 1046-51(2014)
15. Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K,Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K. Influence of uridine diphosphate
glucuronosyltransferase 2B7 -161C<T polymorphism on the concentration ofvalproic acid in pediatric epilepsy patients. Ther Drug Monit. 36(3), 406-9 (2014)16. Saito M, Kondo M, Ohshima M, Deguchi K, Hayashi H, Inoue K, Tsuji D, MasukoT, Itoh K. Identification of anti-CD98 antibody mimotopes for inducing antibodies
with antitumor activity by mimotope immunization. Cancer Sci. 105(4), 396-401(2014)
17. Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K, Itoh K,Kagawa Y, Inoue Y. Risk factors for hyperammonemia in pediatric patients withepilepsy. Epilepsia. 54(6), 983-9 (2013)
18. Tsuji D, Kamezato M, Daimon T, Taku K, Hatori M, Ikeda M, Hayashi H, Inoue K,
Eto T, Itoh K. Retrospective analysis of severe neutropenia in patients receiving
concomitant administration of docetaxel and clarithromycin. Chemotherapy.
59(6),407-13 (2013)
19. Hayashi H, Tazoe Y, Tsuboi S, Horino M, Morishita M, Arai T, Ohshima M,
Matsuyama T, Kosuge K, Yamada H, Tsuji D, Inoue K, Itoh K. A single nucleotide
polymorphism of reduced folate carrier 1 predicts methotrexate efficacy inJapanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet. 28(2),164-8 (2013)
20. Tsuji D, Kim YI, Nakamichi H, Daimon T, Suwa K, Iwabe Y, Hayashi H, Inoue K,Yoshida M, Itoh K. Association of ABCB1 polymorphisms with the antiemeticefficacy of granisetron plus dexamethasone in breast cancer patients. DrugMetab Pharmacokinet. 28(4), 299-304 (2013)
21. Inoue K, Sonobe M, Kawamura Y, Etoh T, Takagi M, Matsumura T, Kikuyama M,Kimura M, Minami S, Utsuki H, Yamazaki T, Suzuki T, Tsuji D, Hayashi H, Itoh K.
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associatedwith adverse events in cancer patients receiving irinotecan-based chemotherapy.
Tohoku J Exp Med. 229(2), 107-14 (2013)
22. Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, Inoue K, Itoh K, Kagawa Y,Inoue Y. Risk factors for hyperammonemia associated with valproic acid therapy
in adult epilepsy patients. Epilepsy Res. 101(3), 202-9 (2012)
23. Inoue K, Ando N, Suzuki E, Hayashi H, Tsuji D, Itoh K. Genotype distributions
and allele frequencies of possible major depressive disorder-associated single
nucleotide polymorphisms, cyclic adenosine monophosphate response elementbinding protein 1 rs4675690 and Piccolo rs2522833, in a Japanese population.
Biol Pharm Bull. 35(2), 265-8 (2012)24. Hayashi H, Tazoe Y, Horino M, Fujimaki-Katoh C, Tsuboi S, Matsuyama T,Kosuge K, Yamada H, Tsuji D, Inoue K, Itoh K. An artifact derived from apseudogene led to the discovery of microRNA binding site polymorphism in the3'-untranslated region of the human dihydrofolate reductase gene. Drug MetabPharmacokinet. 27(2), 263-7 (2012)
25. Ohshima M, Inoue K, Hayashi H, Tsuji D, Mizugaki M, Itoh K. Generation ofAcGFP fusion with single-chain Fv selected from a phage display library
constructed from mice hyperimmunized against 5-methyl 2'-deoxycytidine.
Protein Eng Des Sel. 23(11), 881-8 (2010)

26. Hayashi H, Horino M, Morishita M, Tazoe Y, Tsuboi S, Matsuyama T, Kosuge K,Yamada H, Tsuji D, Inoue K, Itoh K. Dihydrofolate reductase gene intronic 19-bp
deletion polymorphisms in a Japanese population. Drug Metab Pharmacokinet.
25(5), 516-8 (2010)
27. Ohshima M, Tadakuma T, Hayashi H, Inoue K, Itoh K. Generation of arecombinant single-chain variable fragment (scFv) targeting 5-methyl-2'deoxycytidine. J Biochem. 147(1), 135-41 (2010)
28. Miura M, Inoue K, Kagaya H, Saito M, Habuchi T, Satoh S. Inter-individual
difference determinant of prednisolone pharmacokinetics for Japanese renaltransplant recipients in the maintenance stage. Xenobiotica. 39(12), 939-45(2009)
29. Yoshizawa M, Hayashi H, Tashiro Y, Sakawa S, Moriwaki H, Akimoto T, Doi O,Kimura M, Kawarasaki Y, Inoue K, Itoh K. Effect of VKORC1 -1639 G>Apolymorphism, body weight, age, and serum albumin alterations on warfarin
response in Japanese patients. Thromb Res. 124(2), 161-6 (2009)30. Satoh S, Saito M, Inoue T, Kagaya H, Miura M, Inoue K, Komatsuda A, Tsuchiya
N, Suzuki T, Habuchi T. CYP3A5*1 allele associated with tacrolimus troughconcentrations but not subclinical acute rejection or chronic allograft nephropathy
in Japanese renal transplant recipients. Eur J Clin Pharmacol. 65(5), 473-81(2009)
31. Fujiyama N, Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Habuchi T, Suzuki
T. Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid
pharmacokinetics in Japanese renal transplant recipients. Xenobiotica. 39(5),407-14 (2009)32. Fujimaki C, Hayashi H, Tsuboi S, Matsuyama T, Kosuge K, Yamada H, Inoue K,Itoh K. Plasma total homocysteine level and methylenetetrahydrofolate reductase
677C>T genetic polymorphism in Japanese patients with rheumatoid arthritis.
Biomarkers. 14(1), 49-54 (2009)
33. Itoh K, Ohshima M, Sonobe M, Saito M, Yoshida A, Hayashi H, Inoue K, Masuko
T. Antibody epitope peptides as potential inducers of IgG antibodies against CD98
oncoprotein. Cancer Sci. 100(1), 126-31 (2009)
34. Miura M, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T. Telmisartan
pharmacokinetics in Japanese renal transplant recipients. Clin Chim Acta. 399(12), 83-7 (2009)
35. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Habuchi T, Suzuki T.
Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone
pharmacokinetics in renal transplant recipients. Steroids. 73(11), 1052-9 (2008)
36. Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T. Influenceof drug transporters and UGT polymorphisms on pharmacokinetics of phenolic
glucuronide metabolite of mycophenolic acid in Japanese renal transplant
recipients. Ther Drug Monit. 30(5), 559-64 (2008)
37. Saito M, Satoh S, Kagaya H, Tsuruta H, Obara T, Kumazawa T, Inoue T, InoueK, Miura M, Yuasa T, Komatsuda A, Tsuchiya N, Habuchi T. Thrombotic
microangiopathy developing in early stage after renal transplantation with a hightrough level of tacrolimus. Clin Exp Nephrol. 12(4), 312-5 (2008)
38. Satoh S, Kagaya H, Saito M, Inoue T, Miura M, Inoue K, Numakura K, Tsuchiya
N, Tada H, Suzuki T, Habuchi T. Lack of tacrolimus circadian pharmacokinetics
and CYP3A5 pharmacogenetics in the early and maintenance stages inJapanese renal transplant recipients. Br J Clin Pharmacol. 66(2), 207-14 (2008)
39. Kagaya H, Miura M, Satoh S, Inoue K, Saito M, Inoue T, Habuchi T, Suzuki T. No
pharmacokinetic interactions between mycophenolic acid and tacrolimus in renaltransplant recipients. J Clin Pharm Ther. 33(2), 193-201 (2008)
40. Yoshida K, Higuchi H, Takahashi H, Kamata M, Sato K, Inoue K, Suzuki T, ItohK, Ozaki N. Influence of the tyrosine hydroxylase val81met polymorphism andcatechol-O-methyltransferase val158met polymorphism on the antidepressanteffect of milnacipran. Hum Psychopharmacol. 23(2), 121-8 (2008)
41. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Suzuki T, Habuchi T. Influenceof lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one
year after renal transplantation. Ther Drug Monit. 30(1), 46-51 (2008)